The Diagnostic Odyssey: From "Something Is Wrong" to an LMBRD2 Diagnosis

There is often a precise moment. A phrase from a doctor, a test result, a word spoken for the first time. And before that moment, months — sometimes years — during which you knew something was wrong, without anyone being able to tell you what.

This journey has a name: the diagnostic odyssey. For families affected by LMBRD2, it can last a few months or several years. Some children are diagnosed relatively quickly, thanks to an alert geneticist or a broad genetic panel. Others go through long years of uncertainty, accumulating provisional diagnoses before a genomic sequencing test finally reveals the mutation. In rare cases, like Mélanie — whose story you can read on this blog — the diagnosis only comes in adulthood, after a lifetime without answers.

What is universal is not the duration. It is the experience: a path marked by uncertainty, in a medical world that, more often than not, has never heard of LMBRD2.

---

🧩 The First Signs: When Something "Doesn't Add Up"

For most LMBRD2 families, the story begins not with a diagnosis, but with an accumulation of small signs that worry without explaining themselves.

A delay in sitting up. A baby who doesn't babble like others. Late walking, often on tiptoes. Seizures appearing without apparent cause. Language development that stalls, or regresses. Each of these signs, taken in isolation, can have dozens of explanations. It is their combination, their persistence, and their resistance to standard treatments that eventually alerts medical teams.

⚠️ What parents experience at this stage: a form of double isolation. The worry of seeing their child develop differently, and the frustration of not getting answers. Many families report being told "let's wait a few more months," "every child develops at their own pace," or receiving provisional diagnoses — cerebral palsy, autism spectrum disorder, Rett syndrome — that did not hold up under closer examination.

This is not a medical failure. It is the reality of ultra-rare diseases: fewer than 100 known cases worldwide, a single scientific reference article published in 2021. Most pediatricians, neurologists, and even geneticists have never heard of LMBRD2. You cannot diagnose what you do not know.

---

🔬 The Key Test: Genomic Sequencing

The diagnostic turning point always comes with the same test: whole exome sequencing (WES) or, increasingly, whole genome sequencing (WGS).

What is the exome?

Our DNA contains approximately 20,000 genes. The exome represents the "coding" portion of that DNA — the segments that contain the instructions for making proteins. It accounts for only about 1.5% of total DNA, but concentrates the vast majority of mutations responsible for known genetic diseases.

Sequencing the exome means reading all of that 1.5% and comparing it to a reference sequence, looking for anomalies. This is the test that, in virtually all LMBRD2 cases, has identified the mutation.

---

Why does this test sometimes come late?

Several reasons explain why the path to sequencing can be long:

🟡 Its availability and reimbursement vary by country and healthcare system

🟡 It requires specialized teams to interpret the results

🟡 It is often reserved for cases where standard tests have found nothing

🟡 Ordering it depends on the clinical suspicion of the referring physician

🟡 In some regions, access to clinical genetics remains limited or poorly known to families

If your regular doctor has not mentioned this option, it is entirely appropriate to ask for a referral to a clinical genetics team specializing in rare diseases. These are the teams — in university hospitals or specialized centers — who prescribe and interpret these tests.

---

📄 The Genetic Report: Decoding What You Received

When results arrive, they come in the form of a dense report filled with technical terminology. Here are the essential concepts to understand.

Pathogenic variant / Likely pathogenic

These are the categories that designate a mutation considered responsible for the disease. When a report identifies an LMBRD2 gene mutation classified this way, that is the diagnosis.

LMBRD2 mutations are almost always de novo — appearing spontaneously in the child, absent in both parents. This is not a hereditary disease in the classical sense. Neither parent "passed on" the disease: the error occurred during the formation of reproductive cells or at the very beginning of embryonic development. There is no fault, no avoidable cause.

VUS: The Most Destabilizing Category

VUS stands for Variant of Uncertain Significance. It is a mutation detected in the gene, but for which the currently available data cannot yet conclusively determine whether it is responsible for the observed symptoms.

"We were told there was something in the LMBRD2 gene, but that they didn't know if it was the cause. We waited another eighteen months in that uncertainty."

Receiving a VUS means having a partial answer — sometimes harder to live with than no answer at all, because the solution seems within reach yet remains out of grasp.

But VUS classifications are not permanent. They evolve over time, and this is where every family plays a direct role.

---

🔄 Reclassification: Why Every New Family Matters

This is one of the most important — and least known — mechanisms in rare disease genetics.

When a mutation is discovered in only one patient in the world, the data are insufficient to classify it with certainty. But as more patients carrying the same mutation are identified, the evidence accumulates. International databases update. A VUS can become "likely pathogenic," then "pathogenic."

This is why every family that joins the LMBRD2 registry, shares their medical data, and allows their information to be cross-referenced with other families around the world directly contributes to the diagnostic certainty of everyone else.

This reclassification happens primarily through shared international databases:

• ClinVar (NIH): a public database that catalogs genetic variants and their classifications

• DECIPHER (Wellcome Sanger Institute): a platform dedicated to rare variants in developmental disorders

• Matchmaker Exchange: a global network that allows physicians to connect patients with similar variants, regardless of their country

This is precisely what our association does. We actively collect the genetic variants and clinical phenotypes of every identified LMBRD2 patient worldwide — that is, the precise characteristics of each mutation and the symptoms associated with it. These data, consolidated and shared with research teams, directly contribute to the scientific and medical recognition of the disease. Every newly documented case strengthens the collective evidence. If you have received an LMBRD2 diagnosis — confirmed or suspected — contact us. Your case matters, literally.

---

💙 What This Journey Leaves Behind

The diagnostic odyssey leaves marks. Months or years of uncertainty, fruitless consultations, sometimes incorrect diagnoses with inappropriate treatments. A relationship with the medical system shaped by exhaustion or distrust. And often, a silent guilt — did I do enough? did I ask the right questions? — that has no place here.

And then comes the diagnosis. With it, paradoxically, an ambivalent feeling: the relief of finally having a name, combined with the pain of realizing that this name refers to a rare disease with no known curative treatment today. These two emotions coexist, and both are legitimate.

What many families report: having the diagnosis also means joining a community. Stepping out of invisibility. Finding other parents who understand, other children who resemble yours. Being able to finally tell the school, the doctor, the family: "this is what it is."

---

🎯 If You Are Still Looking for Answers

If your child does not yet have a diagnosis but certain signs concern you, here are some concrete steps:

✅ Ask for a referral to a clinical genetics team — these specialists are trained for complex and unexplained clinical presentations. Genomic sequencing is not typically ordered by primary care physicians; it requires a specialist.

✅ Explicitly ask about sequencing — if your child presents with unexplained developmental delay alongside neurological abnormalities, whole exome or genome sequencing is the test to request. It is not always suggested spontaneously: sometimes you need to ask for it.

✅ Keep all medical records — brain imaging reports (MRI), neuropsychological assessments, biological results. Every test is part of the puzzle and will be valuable to the team that ultimately makes the diagnosis.

✅ Contact us — our association is the only one in the world dedicated to LMBRD2. If your child's symptoms resemble what you have read here, we can help guide you and connect you with other families who have walked the same path.

---

🔑 Key Takeaways

🔵 There is no single LMBRD2 diagnostic journey — some children are diagnosed within months, others after years. What varies is access to genomic sequencing and awareness of the mutation among medical teams.

🔵 Whole exome or genome sequencing is the key test — it can and should be requested when facing unexplained neurological presentations.

🔵 A VUS is not a dead end — classifications evolve as more families are identified worldwide.

🔵 Every family that shares their data directly contributes to the diagnostic certainty of all other LMBRD2 patients in the world.

🔵 Joining the LMBRD2 community means both finding support and actively participating in research.

This article is for informational purposes only and does not replace medical advice. For any questions regarding a diagnosis, please consult a clinical geneticist or a specialized rare disease team.

---

🤝 How to Support Our Work

Every family like yours requires tailored support and considerable resources. Our association needs your support to continue assisting affected families, funding research, and creating information and support tools. Every donation, however small, makes a difference.